Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2025)

Historic Change in Acquisitions & Divestments for BridgeBio Pharma (BBIO) over the last 6 years, with Q3 2025 value amounting to $8.0 million.

  • BridgeBio Pharma's Change in Acquisitions & Divestments fell 7481.98% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 9349.63%. This contributed to the annual value of $95.0 million for FY2024, which is 1407.07% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Change in Acquisitions & Divestments stood at $8.0 million, which was down 7481.98% from $31.8 million recorded in Q3 2024.
  • BridgeBio Pharma's Change in Acquisitions & Divestments' 5-year high stood at $186.7 million during Q1 2022, with a 5-year trough of $8.0 million in Q3 2025.
  • Over the past 5 years, BridgeBio Pharma's median Change in Acquisitions & Divestments value was $63.2 million (recorded in 2024), while the average stood at $71.6 million.
  • In the last 5 years, BridgeBio Pharma's Change in Acquisitions & Divestments surged by 24919.53% in 2021 and then tumbled by 9025.68% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Acquisitions & Divestments (Quarter) stood at $75.0 million in 2021, then crashed by 64.17% to $26.9 million in 2022, then rose by 4.23% to $28.0 million in 2023, then increased by 13.44% to $31.8 million in 2024, then crashed by 74.82% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $31.8 million for Q3 2024, and $63.2 million during Q1 2024.